Monday - December 23, 2024
Baylor Scott & White Health: First-of-Its-Kind Breast Cancer Research Study Explores the Impact of Weight Loss Drugs on Recurrence
December 12, 2024
DALLAS, Texas, Dec. 12 (TNSres) -- Baylor Scott and White Health issued the following news release:

* * *

TRIM-EBC/* clinical trial studying whether weight loss from Zepbound(R) (tirzepatide) can lower the risk of breast cancer recurrence by reducing or clearing circulating tumor DNA (ctDNA)

* * *

A breast cancer research study now open at Baylor University Medical Center in Dallas is believed to be the first of its kind to explore the ability . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation
Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products